Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

ClinicalTrials.gov ID: NCT06989112

Public ClinicalTrials.gov record NCT06989112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Study identification

NCT ID
NCT06989112
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
600 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 26, 2025
Primary completion
Jan 18, 2029
Completion
Feb 18, 2031
Last update posted
Sep 2, 2026

2025 – 2031

United States locations

U.S. sites
61
U.S. states
31
U.S. cities
58
Facility City State ZIP Site status
Research Site Tucson Arizona 85704 Withdrawn
Research Site Little Rock Arkansas 72205 Recruiting
Research Site Duarte California 91010 Recruiting
Research Site Irvine California 92618 Recruiting
Research Site La Jolla California 92037 Recruiting
Research Site Palo Alto California 94304 Withdrawn
Research Site San Francisco California 94143 Withdrawn
Research Site Sylmar California 91342 Withdrawn
Research Site Fort Myers Florida 33901 Recruiting
Research Site Miami Florida 33133 Not yet recruiting
Research Site Miami Beach Florida 33140 Recruiting
Research Site Orlando Florida 32804 Not yet recruiting
Research Site St. Petersburg Florida 33705 Recruiting
Research Site Tampa Florida 33612 Recruiting
Research Site West Palm Beach Florida 33401 Recruiting
Research Site Augusta Georgia 30912 Withdrawn
Research Site Honolulu Hawaii 96813 Withdrawn
Research Site Arlington Heights Illinois 60005 Recruiting
Research Site Evanston Illinois 60201 Recruiting
Research Site Shreveport Louisiana 71103 Recruiting
Research Site Baltimore Maryland 21201 Recruiting
Research Site Silver Spring Maryland 20910 Not yet recruiting
Research Site Boston Massachusetts 02111 Recruiting
Research Site Worcester Massachusetts 01655 Withdrawn
Research Site Ann Arbor Michigan 48109 Recruiting
Research Site Detroit Michigan 48201 Withdrawn
Research Site Marshall Minnesota 56258 Not yet recruiting
Research Site Minneapolis Minnesota 55455 Recruiting
Research Site Rochester Minnesota 55905 Recruiting
Research Site Jackson Mississippi 39216 Recruiting
Research Site Springfield Missouri 65804 Recruiting
Research Site St Louis Missouri 63141 Recruiting
Research Site Las Vegas Nevada 89169 Withdrawn
Research Site Lebanon New Hampshire 03756 Recruiting
Research Site Hackensack New Jersey 07601 Recruiting
Research Site Albuquerque New Mexico 87109 Suspended
Research Site New York New York 10016 Withdrawn
Research Site New York New York 10065 Recruiting
Research Site New York New York 10075 Withdrawn
Research Site Charlotte North Carolina 28204 Not yet recruiting
Research Site Winston-Salem North Carolina 27103 Recruiting
Research Site Winston-Salem North Carolina 27157 Not yet recruiting
Research Site Cincinnati Ohio 45220 Recruiting
Research Site Columbus Ohio 43210 Recruiting
Research Site Oklahoma City Oklahoma 73104 Not yet recruiting
Research Site Tulsa Oklahoma 74134 Withdrawn
Research Site Eugene Oregon 97401 Recruiting
Research Site Abington Pennsylvania 19001 Withdrawn
Research Site Philadelphia Pennsylvania 19111 Recruiting
Research Site Pittsburgh Pennsylvania 15224 Recruiting
Research Site Providence Rhode Island 02905 Recruiting
Research Site Charleston South Carolina 29425 Recruiting
Research Site Sioux Falls South Dakota 57105 Recruiting
Research Site Austin Texas 78758 Recruiting
Research Site Fort Worth Texas 76104 Recruiting
Research Site Houston Texas 77030 Recruiting
Research Site San Antonio Texas 78240 Recruiting
Research Site Charlottesville Virginia 22908 Recruiting
Research Site Fairfax Virginia 22031 Recruiting
Research Site Seattle Washington 98133 Withdrawn
Research Site Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 193 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06989112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06989112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →